Recherche
-
Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure
(Graefe's Archive for Clinical and Experimental Ophthalmology. vol. 259, pp. 567–574, 2021-02-02)Article de revueLibre accès -
Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison
(Advances in Therapy, 2020)Article de revueLibre accès -
Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence
(The British Journal of Ophthalmology. vol. 105, n° 11, 2021-10-21)Article de revueLibre accès -
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: The CENTERA Study
(American Journal of Ophthalmology, 2021-02-06)Article de revueLibre accès -
Secondary Stroke Prevention: A Population-Based Cohort Study on Anticoagulation and Antiplatelet Treatments, and the Risk of Death or Recurrence
(Clinical Pharmacology and Therapeutics. vol. 107, n° 2, pp. 443-451, 2020)Article de revue -
Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study
(EP-Europace. vol. 22, n° 2, pp. 205-215, 2020)Article de revue -
Cognitive and Motor Skills of People with Down Syndrome According to Their Perceived Self-Determination
(Journal of Developmental and Physical Disabilities, 2021-03-22)Article de revue -
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial
(The Lancet Infectious Diseases, 2020-11-17)Article de revue -
Failure to Reach a Consensus in Polypharmacy Definition: An Obstacle to Measuring Risks and Impacts-Results of a Literature Review
(Therapeutics and Clinical Risk Management. vol. 16, pp. 57-73, 2020)Article de revueLibre accès -
Treatment resistant depression incidence and prevalence using the French nationwide claims database
(Pharmacoepidemiology and Drug Safety. vol. 30, n° 2, pp. 169–177, 2021-02)Article de revue